按需腹腔灌注重组人血管内皮抑制素治疗胃癌腹水的临床观察  

Clinical Observation of on-Demand Intraperitoneal Injection of Endostar on Advanced Gastric Cancers with Malignant Ascites

作　　者：王志明[1] 刘天舒[1] 李倩[1] 冯艺[1] 庄荣源[1] 宋燕[1] 陈勇[1] 周宇红[1] 金文[1] 

机构地区：[1]复旦大学附属中山医院肿瘤内科,上海200052

出　　处：《中国临床医学》2011年第4期462-464,共3页Chinese Journal of Clinical Medicine

摘　　要：目的:观察重组人血管内皮抑制素按需腹腔给药治疗胃癌腹水的疗效,并评价重组人血管内皮抑制素腹腔治疗的耐受性和安全性。方法:5例口服氟尿嘧啶类药物化疗过程中的晚期胃癌患者,患者病灶稳定,但出现腹水,引流腹腔内积液后,腹腔灌注重组人血管内皮抑制素30mg。根据患者腹胀程度,按需引流腹水并腹腔灌注重组人血管内皮抑制素治疗,评价疗效、生活质量、腹水蛋白丢失量及不良反应。结果:5例患者均可进行客观疗效及安全性评价,全组患者腹水生成量减少,生活质量改善,腹水蛋白丢失量减少,无药物相关不良反应。结论:在胃癌实体病灶增殖控制的患者中,按需腹腔灌注重组人血管内皮抑制素能很好地控制恶性腹水、减轻症状、改善生活质量,安全性好。Objective：To observe the clinical efficacy of on-demand injection of endostar（recombinant human endostatin,a new generation of anti-angiogenesis agent） on ascites of advanced gastric cancers,and evaluate the safety and tolerability of intraperitoneal application of the endostar.Methods： Oral fluoropyrimidine were applied for 5 patients with advanced gastric cancer for maintenance therapy.During the procedure of maintenance therapy,the 5 patients emerged noticeable symptoms of ascites,but with stable tumor masses.Following a maximum release of peritoneal cavity fluid,endostar 30mg was injected into peritoneal cavity.Then palliative withdrawal of fluids and on-demand intraperitoneal injections of endostar were given according to the symptoms of abdominal distension,and to investigate its clinical efficacy,quality of life,loss of ascites protein,as well as toxicity.Results： Five cases of patients could be evaluated by its efficacy and safety.All patients were found to decrease amounts of peritoneal cavity fluid,reduce loss of ascites protein and improve their quality of life but without drug-related toxicity.Conclusions： On-demand intraperitoneal injection of endostatin can better control the malignant ascites,reduce the clinical symptoms,improve the patients quality of life in the patients with advanced gastric cancers.Clinical safety is better.

关 键 词：重组人血管内皮抑制素 胃癌 腹水 

分 类 号：R442.5[医药卫生—诊断学]